These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 14567545)

  • 21. Substituted 3-amino biaryl propionic acids as potent VLA-4 antagonists.
    Kopka IE; Lin LS; Mumford RA; Lanza T; Magriotis PA; Young D; DeLaszlo SE; MacCoss M; Mills SG; Van Riper G; McCauley E; Lyons K; Vincent S; Egger LA; Kidambi U; Stearns R; Colletti A; Teffera Y; Tong S; Owens K; Levorse D; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2415-8. PubMed ID: 12161146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melanoma cell adhesion can be blocked by heparin in vitro: suggestion of VLA-4 as a novel target for antimetastatic approaches.
    Fritzsche J; Simonis D; Bendas G
    Thromb Haemost; 2008 Dec; 100(6):1166-75. PubMed ID: 19132244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent alpha 4 beta 1 peptide antagonists as potential anti-inflammatory agents.
    Jackson DY; Quan C; Artis DR; Rawson T; Blackburn B; Struble M; Fitzgerald G; Chan K; Mullins S; Burnier JP; Fairbrother WJ; Clark K; Berisini M; Chui H; Renz M; Jones S; Fong S
    J Med Chem; 1997 Oct; 40(21):3359-68. PubMed ID: 9341911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbon monoxide down-regulates α4β1 integrin-specific ligand binding and cell adhesion: a possible mechanism for cell mobilization.
    Chigaev A; Smagley Y; Sklar LA
    BMC Immunol; 2014 Oct; 15():52. PubMed ID: 25367365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent cyclic peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion. Discovery of compounds like cyclo(MePhe-Leu-Asp-Val-D-Arg-D-Arg) (ZD7349) compatible with depot formulation.
    Dutta AS; Gormley JJ; Coath M; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Ferguson R; Halterman T; Jamieson A; Moors JA; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
    J Pept Sci; 2000 Aug; 6(8):398-412. PubMed ID: 10969869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular basis for the dynamic strength of the integrin alpha4beta1/VCAM-1 interaction.
    Zhang X; Craig SE; Kirby H; Humphries MJ; Moy VT
    Biophys J; 2004 Nov; 87(5):3470-8. PubMed ID: 15347595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of beta 1 integrin intracytoplasmic domains in the regulation of VLA-4-mediated adhesion of human T cells to VCAM-1 under flow conditions.
    Rosenthal-Allieri MA; Ticchioni M; Breittmayer JP; Shimizu Y; Bernard A
    J Immunol; 2005 Jul; 175(2):1214-23. PubMed ID: 16002725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and assay of retro-α4β1 integrin-targeting motifs.
    Dattoli SD; De Marco R; Baiula M; Spampinato S; Greco A; Tolomelli A; Gentilucci L
    Eur J Med Chem; 2014 Feb; 73():225-32. PubMed ID: 24412498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Binding between heparin and the integrin VLA-4.
    Schlesinger M; Simonis D; Schmitz P; Fritzsche J; Bendas G
    Thromb Haemost; 2009 Nov; 102(5):816-22. PubMed ID: 19888514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential regulation of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity by CC chemokines in monocytes: implications for transendothelial chemotaxis.
    Weber C; Alon R; Moser B; Springer TA
    J Cell Biol; 1996 Aug; 134(4):1063-73. PubMed ID: 8769427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulphonamide-based small molecule VLA-4 antagonists.
    Stasiak M; Mehlin C; Boni E; Vaisar T; Little T; Kim HO; Qabar M
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3875-8. PubMed ID: 14552799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists.
    Doherty GA; Yang GX; Borges E; Chang LL; MacCoss M; Tong S; Kidambi U; Egger LA; McCauley E; Van Riper G; Mumford RA; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2002 Jun; 12(11):1501-5. PubMed ID: 12031329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The identification and optimization of orally efficacious, small molecule VLA-4 antagonists.
    Huryn DM; Konradi AW; Ashwell S; Freedman SB; Lombardo LJ; Pleiss MA; Thorsett ED; Yednock T; Kennedy JD
    Curr Top Med Chem; 2004; 4(14):1473-84. PubMed ID: 15544538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of very late antigen-4 (VLA-4, alpha4beta1 integrin) allosteric antagonists.
    Chigaev A; Wu Y; Williams DB; Smagley Y; Sklar LA
    J Biol Chem; 2011 Feb; 286(7):5455-63. PubMed ID: 21131351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VLA-4 antagonists: potent inhibitors of lymphocyte migration.
    Yang GX; Hagmann WK
    Med Res Rev; 2003 May; 23(3):369-92. PubMed ID: 12647315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-isonicotinoyl-(L)-4-aminophenylalanine derivatives as tight binding VLA-4 antagonists.
    Doherty GA; Yang GX; Borges E; Tong S; McCauley ED; Treonz KM; Van Riper G; Pacholok S; Si Q; Koo GC; Shah K; Mumford RA; Hagmann WK
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1891-5. PubMed ID: 12749892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and evaluation of potent, cysteine-based alpha4beta1 integrin antagonists.
    Archibald SC; Head JC; Linsley JM; Porter JR; Robinson MK; Shock A; Warrellow GJ
    Bioorg Med Chem Lett; 2000 May; 10(9):993-5. PubMed ID: 10853676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers.
    Klemke M; Weschenfelder T; Konstandin MH; Samstag Y
    J Cell Physiol; 2007 Aug; 212(2):368-74. PubMed ID: 17352405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent cyclic monomeric and dimeric peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion based on the Ile-Leu-Asp-Val tetrapeptide.
    Dutta AS; Crowther M; Gormley JJ; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Jamieson A; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
    J Pept Sci; 2000 Jul; 6(7):321-41. PubMed ID: 10946997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ligand binding of leukocyte integrin very late antigen-4 involves exposure of sulfhydryl groups and is subject to redox modulation.
    Liu SY; Tsai MY; Chuang KP; Huang YF; Shieh CC
    Eur J Immunol; 2008 Feb; 38(2):410-23. PubMed ID: 18196516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.